-
Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;36:106-16.. pdf -
Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses.
von Kaisenberg CS, Brand-Saberi B, Jonat W, Nicolaides KH.
Der Gynäkologe 1999;32:193-199. -
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:231-7. -
Assessment of umbilical arterial and venous flow using color Doppler.
Lees C, Albaiges G, Deane C, Parra M, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;14:250-5. -
International, collaborative assessment of 146,000 prenatal karyotypes: expected limitations if only chromosome-specific probes and fluorescent in-situ hybridization are used.
Evans MI, Henry GP, Miller WA, Bui TH, Snidjers RJ, Wapner RJ, Miny P, Johnson MP, Peakman D, Johnson A, Nicolaides K, Holzgreve W, Ebrahim SA, Babu R, Jackson L.
Hum Reprod 1999;14:1213-6. -
First trimester umbilical venous Doppler sonography in chromosomally normal and abnormal fetuses.
Brown RN, Di Luzio L, Gomes C, Nicolaides KH.
J Ultrasound Med 1999;18:543-6. -
Investigation of maternal blood enriched for fetal cells: role in screening and diagnosis of fetal trisomies.
Al-Mufti R, Hambley H, Farzaneh F, Nicolaides KH.
Am J Med Genet 1999;2;85:66-75.